ZA200309260B - Aromatic hydroxamic acid derivatives useful as HDAC inhibitors. - Google Patents

Aromatic hydroxamic acid derivatives useful as HDAC inhibitors. Download PDF

Info

Publication number
ZA200309260B
ZA200309260B ZA200309260A ZA200309260A ZA200309260B ZA 200309260 B ZA200309260 B ZA 200309260B ZA 200309260 A ZA200309260 A ZA 200309260A ZA 200309260 A ZA200309260 A ZA 200309260A ZA 200309260 B ZA200309260 B ZA 200309260B
Authority
ZA
South Africa
Prior art keywords
thiophene
hydroxyamide
dicarboxylic acid
benzylamide
amide
Prior art date
Application number
ZA200309260A
Other languages
English (en)
Inventor
Ulrike Leser-Reiff
Tim Sattelkau
Gerd Zimmermann
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of ZA200309260B publication Critical patent/ZA200309260B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C07D213/40—Acylated substituent nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C07C259/10—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/16—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with acylated ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/10—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/14—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/58—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
ZA200309260A 2001-06-15 2003-11-27 Aromatic hydroxamic acid derivatives useful as HDAC inhibitors. ZA200309260B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01114496 2001-06-15

Publications (1)

Publication Number Publication Date
ZA200309260B true ZA200309260B (en) 2005-02-28

Family

ID=8177731

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200309260A ZA200309260B (en) 2001-06-15 2003-11-27 Aromatic hydroxamic acid derivatives useful as HDAC inhibitors.

Country Status (33)

Country Link
US (2) US6784173B2 (bg)
EP (1) EP1401824B1 (bg)
JP (1) JP4195377B2 (bg)
KR (2) KR20090059172A (bg)
CN (1) CN1271066C (bg)
AR (1) AR036055A1 (bg)
AT (1) ATE343569T1 (bg)
AU (1) AU2002355626B2 (bg)
BG (1) BG108450A (bg)
BR (1) BR0210424A (bg)
CA (1) CA2449804A1 (bg)
CO (1) CO5540280A2 (bg)
CZ (1) CZ200425A3 (bg)
DE (1) DE60215652T2 (bg)
EC (1) ECSP034896A (bg)
ES (1) ES2272800T3 (bg)
GT (1) GT200200121A (bg)
HK (1) HK1065787A1 (bg)
HR (1) HRP20031019A2 (bg)
HU (1) HUP0401233A3 (bg)
IL (1) IL159097A0 (bg)
MA (1) MA27041A1 (bg)
MX (1) MXPA03011501A (bg)
NO (1) NO20035555D0 (bg)
NZ (1) NZ529874A (bg)
PA (1) PA8548001A1 (bg)
PE (1) PE20030086A1 (bg)
PL (1) PL366729A1 (bg)
RS (1) RS98203A (bg)
RU (1) RU2289580C2 (bg)
SK (1) SK172004A3 (bg)
WO (1) WO2003011851A2 (bg)
ZA (1) ZA200309260B (bg)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6822267B1 (en) * 1997-08-20 2004-11-23 Advantest Corporation Signal transmission circuit, CMOS semiconductor device, and circuit board
OA12789A (en) 2002-03-13 2006-07-10 Janssen Pharmaceutica Nv Carbonylamino-derivatives as novel inhibitors of histone deacetylase.
PL212089B1 (pl) * 2002-03-13 2012-08-31 Janssen Pharmaceutica Nv Związki heterocykliczne jako inhibitory deacetylazy histonowej, kompozycja farmaceutyczna je zawierająca, ich zastosowanie, sposób wytwarzania, sposób wykrywania lub identyfikacji HDAC oraz kompozycja
WO2003082288A1 (en) * 2002-04-03 2003-10-09 Topotarget Uk Limited Carbamic acid compounds comprising a piperazine linkage as hdac inhibitors
US7154002B1 (en) 2002-10-08 2006-12-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
US7250514B1 (en) 2002-10-21 2007-07-31 Takeda San Diego, Inc. Histone deacetylase inhibitors
TW200418825A (en) * 2002-12-16 2004-10-01 Hoffmann La Roche Novel (R)-and (S) enantiomers of thiophene hydroxamic acid derivatives
TW200424174A (en) 2003-02-06 2004-11-16 Hoffmann La Roche New TP diamide
US7208491B2 (en) 2003-02-07 2007-04-24 Hoffmann-La Roche Inc. N-monoacylated o-phenylenediamines
JP2006520796A (ja) * 2003-03-17 2006-09-14 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼインヒビター
TW200424187A (en) * 2003-04-04 2004-11-16 Hoffmann La Roche New oxime derivatives and their use as pharmaceutically active agents
US7935724B2 (en) * 2003-10-09 2011-05-03 Merck Hdac Research, Llc Thiophene and benzothiophene hydroxamic acid derivatives
US20050137234A1 (en) * 2003-12-19 2005-06-23 Syrrx, Inc. Histone deacetylase inhibitors
WO2005065681A1 (en) * 2003-12-19 2005-07-21 Takeda San Diego, Inc. N- hydroxy-3-(3-(1h-imidazol-2-yl)-phenyl)-acrylamide derivatives and related compounds as histone deacetylase (hdac) inhibitors for the treatment of cancer
US7217723B2 (en) 2004-02-02 2007-05-15 Eisai Co., Ltd. Heterocyclic compound having oxime group
US7521473B2 (en) * 2004-02-25 2009-04-21 Wyeth Inhibitors of protein tyrosine phosphatase 1B
WO2005081960A2 (en) * 2004-02-25 2005-09-09 Wyeth Inhibitors of protein tyrosine phosphatase 1b
US7423060B2 (en) 2004-06-14 2008-09-09 Hoffman-La Roche Inc. Thiophene hydroxamic acid derivatives and their use as HDAC inhibitors
WO2005121119A1 (en) * 2004-06-14 2005-12-22 F. Hoffmann-La Roche Ag Hydroxamates, their manufacture and use as pharmaceutical agents
WO2005121134A1 (en) * 2004-06-14 2005-12-22 F. Hoffmann-La Roche Ag Thiophene derivatives, their manufacture and use as pharmaceutical agents
BRPI0512676B8 (pt) 2004-07-28 2021-05-25 Janssen Pharmaceutica Nv derivados de indolil alquil amina substituídos como inibidores de histona desacetilase, composição farmacêutica que os compreende, seus processos de preparação e uso
KR100620488B1 (ko) 2004-08-13 2006-09-08 연세대학교 산학협력단 신규한 히스톤 디아세틸라아제 억제제 및 이의 제조방법
EP1824831A2 (en) * 2004-12-16 2007-08-29 Takeda San Diego, Inc. Histone deacetylase inhibitors
US20100087328A1 (en) * 2005-03-01 2010-04-08 The Regents Of The University Of Michigan Brm expression and related diagnostics
US7604939B2 (en) * 2005-03-01 2009-10-20 The Regents Of The University Of Michigan Methods of identifying active BRM expression-promoting HDAC inhibitors
EP1874755A4 (en) * 2005-04-20 2010-04-28 Merck Sharp & Dohme BENZOTHIOPHENE-hydroxamic acid derivatives
GB0509225D0 (en) 2005-05-05 2005-06-15 Chroma Therapeutics Ltd Inhibitors of enzymatic activity
GB0509223D0 (en) 2005-05-05 2005-06-15 Chroma Therapeutics Ltd Enzyme inhibitors
WO2006122319A2 (en) * 2005-05-11 2006-11-16 Takeda San Diego, Inc. Histone deacetylase inhibitors
JP2009501236A (ja) * 2005-07-14 2009-01-15 タケダ サン ディエゴ インコーポレイテッド ヒストンデアセチラーゼ阻害剤
GB0518237D0 (en) * 2005-09-07 2005-10-19 Angeletti P Ist Richerche Bio Therapeutic compounds
AR057579A1 (es) * 2005-11-23 2007-12-05 Merck & Co Inc Compuestos espirociclicos como inhibidores de histona de acetilasa (hdac)
WO2007069020A2 (en) * 2005-12-15 2007-06-21 Vicuron Pharmaceuticals Inc. N-hydroxyamide derivatives possessing antibacterial activity
WO2007084390A2 (en) * 2006-01-13 2007-07-26 Takeda San Diego, Inc. Histone deacetylase inhibitors
CA2630717C (en) 2006-01-19 2015-02-24 Janssen Pharmaceutica N.V. Pyridine and pyrimidine derivatives as inhibitors of histone deacetylase
GB0603041D0 (en) * 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
GB0619753D0 (en) 2006-10-06 2006-11-15 Chroma Therapeutics Ltd Enzyme inhibitors
CN101553475B (zh) 2006-10-30 2013-04-24 色品疗法有限公司 作为组蛋白脱乙酰基酶抑制剂的异羟肟酸
GB0713686D0 (en) * 2007-07-13 2007-08-22 Addex Pharmaceuticals Sa New compounds 2
CA2701115A1 (en) * 2007-10-04 2009-04-09 Merck Sharp & Dohme Corp. N-hydroxy-naphthalene dicarboxamide and n-hydroxy-biphenyl-dicarboxamide compounds as histone deacetylase inhibitors
CA2735593C (en) 2008-09-03 2017-08-15 Repligen Corporation Compositions including 6-aminohexanoic acid derivatives as hdac inhibitors
GB0903480D0 (en) 2009-02-27 2009-04-08 Chroma Therapeutics Ltd Enzyme Inhibitors
EP3524324A1 (en) 2011-02-28 2019-08-14 BioMarin Pharmaceutical Inc. Histone deacetylase inhibitors
US10059723B2 (en) 2011-02-28 2018-08-28 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
US8957066B2 (en) 2011-02-28 2015-02-17 Biomarin Pharmaceutical Inc. Histone deacetylase inhibitors
KR20150132345A (ko) 2013-03-15 2015-11-25 바이오마린 파머수티컬 인크. Hdac 저해제
EP2826769A1 (en) 2013-07-18 2015-01-21 Institut de Recherche pour le Développement ( IRD) Compounds for the treatment and/or prevention of parasitic diseases and method of production thereof
KR101536050B1 (ko) * 2013-07-30 2015-07-13 충북대학교 산학협력단 신규 이사틴 기반 히드록삼산 및 이를 유효성분으로 포함하는 항암용 조성물
EP3062783B1 (en) * 2013-10-18 2020-08-12 The General Hospital Corporation Imaging histone deacetylases with a radiotracer using positron emission tomography
US10287255B2 (en) * 2014-03-12 2019-05-14 Chong Kun Dang Pharmaceutical Corp. Compounds as histone deacetylase 6 inhibitors and pharmaceutical compositions comprising the same
WO2019185413A1 (en) 2018-03-27 2019-10-03 Basf Se Pesticidal substituted cyclopropyl derivatives
WO2024123700A1 (en) * 2022-12-05 2024-06-13 The General Hospital Corporation Histone deacetylase inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3825554A (en) * 1969-06-13 1974-07-23 Atlantic Richfield Co Method for preparing cyclic nitrile carbonates
JPS54148743A (en) * 1978-05-12 1979-11-21 Asahi Chem Ind Co Ltd Production of methoclopramide
US5369108A (en) * 1991-10-04 1994-11-29 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
US5700811A (en) 1991-10-04 1997-12-23 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and method of use thereof
US6174905B1 (en) 1996-09-30 2001-01-16 Mitsui Chemicals, Inc. Cell differentiation inducer
AUPO721997A0 (en) 1997-06-06 1997-07-03 Queensland Institute Of Medical Research, The Anticancer compounds
ATE514674T1 (de) 1999-11-23 2011-07-15 Methylgene Inc Inhibitoren für histone-deacetylase

Also Published As

Publication number Publication date
BG108450A (bg) 2005-01-31
NZ529874A (en) 2004-12-24
US20030013757A1 (en) 2003-01-16
EP1401824B1 (en) 2006-10-25
CN1271066C (zh) 2006-08-23
IL159097A0 (en) 2004-05-12
CA2449804A1 (en) 2003-02-13
MA27041A1 (fr) 2004-12-20
WO2003011851A2 (en) 2003-02-13
JP2005502641A (ja) 2005-01-27
CO5540280A2 (es) 2005-07-29
KR20090059172A (ko) 2009-06-10
BR0210424A (pt) 2004-08-17
JP4195377B2 (ja) 2008-12-10
DE60215652D1 (de) 2006-12-07
RU2289580C2 (ru) 2006-12-20
US20040214862A1 (en) 2004-10-28
KR100910958B1 (ko) 2009-08-05
RU2003137578A (ru) 2005-05-20
PA8548001A1 (es) 2003-01-24
PL366729A1 (en) 2005-02-07
ATE343569T1 (de) 2006-11-15
HUP0401233A2 (hu) 2004-10-28
GT200200121A (es) 2003-06-19
CN1516697A (zh) 2004-07-28
HUP0401233A3 (en) 2007-05-29
US6784173B2 (en) 2004-08-31
MXPA03011501A (es) 2004-03-09
WO2003011851A3 (en) 2003-09-18
ECSP034896A (es) 2004-01-28
RS98203A (en) 2007-02-05
EP1401824A2 (en) 2004-03-31
KR20040018270A (ko) 2004-03-02
DE60215652T2 (de) 2007-08-23
AU2002355626B2 (en) 2008-09-25
HK1065787A1 (en) 2005-03-04
AR036055A1 (es) 2004-08-04
CZ200425A3 (cs) 2004-04-14
NO20035555D0 (no) 2003-12-12
ES2272800T3 (es) 2007-05-01
HRP20031019A2 (en) 2005-08-31
SK172004A3 (en) 2004-07-07
PE20030086A1 (es) 2003-02-08

Similar Documents

Publication Publication Date Title
EP1401824B1 (en) Aromatic hydroxamic acid derivatives useful as hdac inhibitors
AU2002355626A1 (en) Aromatic hydroxamic acid derivatives useful as HDAC inhibitors
AU2002216074B2 (en) Tetralone derivatives
US7501451B2 (en) Mono-acylated o-phenylendiamines derivatives
US7098241B2 (en) Thiophene hydroxamic acid derivatives
AU2002216074A1 (en) Tetralone derivatives
AU2003241453A1 (en) Aminotetralin-derived urea modulators of vanilloid vr1 receptor
CA2442994A1 (en) Tricyclic alkylhydroxamates, their preparation and their use as cell proliferation inhibitors
ZA200304264B (en) Tetrahydropyridine derivatives, their preparation and their use as cell proliferation inhibitors.
DK1737815T3 (en) THIO-SUBSTITUTED BIARYL METHANSULPHINYL DERIVATIVES
EP1399431B1 (en) Novel nitriles useful as reversible inhibitors of cysteine proteases
MX2009001611A (es) Amidas con dos sustituyentes aromaticos como inhibidores del transportador de glicina 1 (glyt-1).
JP2008501665A (ja) チオフェンヒドロキサム酸誘導体及びｈｄａｃ阻害剤としてのこれらの使用